Sign In
Buy ABSI
$10.21
-0.390 (-3.68%)
At Close: Jul 13, 2026
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
10:55am, Monday, 13'th Jul 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the pos
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
01:01pm, Thursday, 02'nd Jul 2026
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
11:26am, Thursday, 25'th Jun 2026
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
07:20am, Thursday, 25'th Jun 2026
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
09:09am, Wednesday, 24'th Jun 2026
Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, whil
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
06:35am, Wednesday, 24'th Jun 2026
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
06:30am, Wednesday, 24'th Jun 2026
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
01:12am, Wednesday, 10'th Jun 2026
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
05:22pm, Friday, 05'th Jun 2026
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 20'th May 2026
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generativ
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
08:01am, Friday, 08'th May 2026
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
11:26pm, Thursday, 07'th May 2026
Absci Corporation (ABSI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
04:05pm, Thursday, 07'th May 2026
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling fro
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:11pm, Monday, 04'th May 2026
VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generativ
